Antibacterial Agents TRIZ Cases

A triblock copolymer emulsion encapsulates hydrophilic active pharmaceutical ingredients in a stable water-in-oil matrix.

Segmenting apoptosis from necrosis, the indole compound inhibits uncontrolled cell death to treat hepatic functional impairment.

Heteroaryl compounds modulate kinase activity to address toxicity and efficacy limitations in existing treatments.

Direct detection of Mycobacterium tuberculosis nucleotide sequences and polypeptides in enriched hematopoietic stem cell populations.

Recombinant antibody production methods isolate cDNAs encoding heavy and light chains to generate stable immunoglobulins.

Tetrahydropyridine derivatives inhibit the FabI enzyme to block bacterial fatty acid biosynthesis and treat drug-resistant strains.

C. perfringens alpha toxoid vaccine induces anti-alpha toxin antibodies in hens, reducing necrotic enteritis lesions in challenged progeny.

Vaccinia virus complement control protein and factor H regulate complement activation to reduce inflammatory damage while neutralizing influenza A virus.

Antibodies against S. aureus alpha toxin inhibit Pseudomonas aeruginosa growth, addressing multidrug resistance in polybacterial infections.

Enantiomeric bicyclic heteroaromatic compounds inhibit bacterial methionyl tRNA synthetase with high selectivity against mammalian cells.

Azobenzene-modified linear oligopeptides cross-link with multi-arm beta-cyclodextrin to form light-responsive antibacterial agents.

A CXCL9 peptide fragment inhibits neutrophil recruitment to reduce lung inflammation.

Recombinant antigenic peptides differentiate active tuberculosis from immunity without live bacteria.

A DNA condensation-inducing compound followed by an Eis inhibitor targets Mycobacterium tuberculosis.

Tetrahydronaphthalen-2-ol derivatives act as selective estrogen receptor beta agonists to prevent hormone refractory tumor development.

Hexadeca ammonium-modified zinc phthalocyanine complexes prevent aqueous aggregation while enabling rapid metabolism to suppress tumors.

Alpha-substituted beta-lactam-siderophore conjugates exploit bacterial iron transport systems to bypass outer membrane barriers and efflux pumps.

Modified oxazolidinone derivatives combat multi-drug resistant bacteria by varying substituents to enhance efficacy against resistant strains.

Selective peptides block viral replication by targeting extrachromosomal DNA without harming cellular genes.

Multi-antigen diagnostic assays resolve the contradiction between test simplicity and accuracy by detecting diverse immune responses across populations.

Specific pea protein hydrolysate sequences prevent bacterial adhesion, avoiding antibiotic resistance and reducing gastritis risk.

Neutralizing human anti-M-CSF antibodies prevent monocyte proliferation and bone destruction in rheumatoid arthritis.

Sodium formate sensitizes carbapenem-resistant Gram-negative bacteria to aminoglycosides, enabling effective treatment at lower antibiotic doses.

Pyrido[4,3-d]pyrimidin-5-one derivatives inhibit protein kinases to treat diseases like cancer while improving safety profiles.

Extracting toxic binding domains from Protein A creates non-toxic vaccine antigens that neutralize virulence factors and prevent abscess formation.

Systematic structural parameter changes in tetracycline compounds overcome bacterial resistance while maintaining broad-spectrum efficacy.

PsIG protein hydrolyzes extracellular polysaccharides to dismantle biofilms, restoring antibiotic susceptibility against resistant Pseudomonas infections.

Engineered fusion polypeptides merge distinct receptor components to inhibit IL-4 and IL-13 activities, resolving specificity limitations in existing therapies.

Fusion proteins CT005 and CT681 enable rapid antibody detection for Chlamydia trachomatis.

Pyrimidine derivatives inhibit ALK kinase to treat neoplastic diseases, overcoming inadequate therapeutic options.

Ketolide compounds with heteroaryl rings deliver targeted antimicrobial activity, resolving insufficient effectiveness against resistant strains.

A vaccine composition uses fibronectin binding proteins combined with an iscom matrix complex to promote humoral and cellular immunity.

Pyridinium ionic liquid catalyzes a one-pot four-component reaction to synthesize an imidazole derivative, replacing hazardous solvents and improving yields.

A pharmaceutical composition combining an antibiotic, corticosteroid, and organic acid to stabilize the formulation.

A CPS-protein immunogenic conjugate stimulates humoral and cellular immune responses against Burkholderia pseudomallei.

Clay and talc combined with binders improve structural integrity while reducing brittleness in low-cost cleansing bars.

A natural salve softens skin to facilitate active ingredient absorption.

Deuterated beta-lactam antibiotics replace hydrogen with deuterium to extend half-life and overcome bacterial resistance mechanisms.

Specific lytic bacteriophages lyse Clostridium perfringens, resolving antibiotic resistance trade-offs while preserving microbiome stability.

Combining GM-CSF and IL-17 neutralizers reduces joint inflammation and cartilage destruction beyond single-target efficacy.

Engineered Fc region enables localized tumor activation via crosslinking, resolving hepatotoxicity trade-offs while maintaining cross-species efficacy.

Water-soluble PBD dimer linkers prevent protein aggregation in aqueous buffers while maintaining cytotoxic DNA binding affinity.

A silica formulation adsorbs cashew nut shell liquid using particles sized 150 μm or more.

Acid-triggered acetal and orthoester bonds enable rapid intracellular release while preventing premature cleavage in blood circulation.

NAB815 polymyxin derivative reduces positive charges to lower kidney toxicity, enabling effective Gram-negative bacterial treatment.